Modulation of Inflammation by Medium Cut Off Membranes (MCO-IF)
Primary Purpose
Cardiovascular Diseases, End Stage Renal Disease
Status
Unknown status
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Medium cut off dialysis
Standard High Flux Dialyzer
Sponsored by
About this trial
This is an interventional treatment trial for Cardiovascular Diseases
Eligibility Criteria
Inclusion Criteria:
- time since initiation of dialysis > 3 months
- age > 18 years
Exclusion Criteria:
- time since initiation of dialysis < 3 months
- age < 18 years
- ongoing acute or chronic infection/malignoma, because this will interfere with inflammatory baseline values
- major surgery less than 2 weeks before inclusion in the study
- pregnancy
- mental illness
- lack of written and informed consent
Sites / Locations
- Department of nephrology, Klinikum rechts der IsarRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
MCO Dialysis
Standard High Flux Dialysis
Arm Description
Theranova Dialyzer
Standard High Flux Dialyzer
Outcomes
Primary Outcome Measures
Change in inflammation
change of inflammatory score (inflammatory score is derived from multiple biomarkers)
Secondary Outcome Measures
Change in calcification status
calcification score derived from several pro- and anticalcifying biomarkers
change in calcification propensity
this values measures the resistence of serum to a calcification stimulus
Full Information
NCT ID
NCT03270371
First Posted
August 25, 2017
Last Updated
August 29, 2017
Sponsor
Technical University of Munich
1. Study Identification
Unique Protocol Identification Number
NCT03270371
Brief Title
Modulation of Inflammation by Medium Cut Off Membranes
Acronym
MCO-IF
Official Title
Medium-term Modulation of the Inflammatory Profile by Medium-cut Off Membranes in Patients With End Stage Renal Disease
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Unknown status
Study Start Date
September 1, 2017 (Anticipated)
Primary Completion Date
October 2018 (Anticipated)
Study Completion Date
February 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Technical University of Munich
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study examines whether medium-cut off dialysis results in improved blood purification of large middle molecules e.g. inflammatory molecules compared to hemodialysis (HD) treatments with conventional high-flux dialyzers.
Detailed Description
Cardiovascular events and sepsis remain the leading causes of mortality in patients on maintenance hemodialysis. Thus expectancy of life for these patients is comparable to the prognosis of metastasized cancer. So far the exact mechanisms causing excess mortality in hemodialysis patients remain elusive, but chronic inflammation seems to play a central role in the pathogenesis of cardiovascular disease in HD patients.
Keeping this in mind the Theranova medium-cut off membrane, with its ability to clear middle molecules (0,5-50 kDa), seems suitable to further improve clearance of inflammatory mediators as the non-protein bound inflammatory mediators lie within the cut off range of this membrane. The investigators designed this study to get information on the changes in the inflammatory milieu in dialysis patients when using medium-cut off membranes which are know to significantly reduce cytokines compared to standard high-flux dialyzers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Diseases, End Stage Renal Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Medium cut off Dialyzer compared with standard of care High-Flux Dialyzer (Fx Cor Diax 60®). No others changes in our standard of care maintenance dialysis is planned, dialysis specific parameters such as blood flow will be kept unchanged during the study period).
Masking
None (Open Label)
Masking Description
no masking
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
MCO Dialysis
Arm Type
Experimental
Arm Description
Theranova Dialyzer
Arm Title
Standard High Flux Dialysis
Arm Type
Active Comparator
Arm Description
Standard High Flux Dialyzer
Intervention Type
Device
Intervention Name(s)
Medium cut off dialysis
Other Intervention Name(s)
Theranova Dialyzer
Intervention Description
Hemodialysis
Intervention Type
Device
Intervention Name(s)
Standard High Flux Dialyzer
Intervention Description
Hemodialysis
Primary Outcome Measure Information:
Title
Change in inflammation
Description
change of inflammatory score (inflammatory score is derived from multiple biomarkers)
Time Frame
240 days (cross-over design, multiple measurements)
Secondary Outcome Measure Information:
Title
Change in calcification status
Description
calcification score derived from several pro- and anticalcifying biomarkers
Time Frame
240 days (cross-over design, multiple measurements)
Title
change in calcification propensity
Description
this values measures the resistence of serum to a calcification stimulus
Time Frame
240 days (cross-over design, multiple measurements)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
time since initiation of dialysis > 3 months
age > 18 years
Exclusion Criteria:
time since initiation of dialysis < 3 months
age < 18 years
ongoing acute or chronic infection/malignoma, because this will interfere with inflammatory baseline values
major surgery less than 2 weeks before inclusion in the study
pregnancy
mental illness
lack of written and informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christoph Schmaderer, MD
Phone
0049894140
Ext
5053
Email
christoph.schmaderer@mri.tum.de
First Name & Middle Initial & Last Name or Official Title & Degree
Georg Lorenz, MD
Phone
0049894140
Ext
6704
Email
georg.lorenz@mri.tum.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christoph Schmaderer, MD
Organizational Affiliation
attending Department of Nephrology, Klinikum rechts der Isar
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of nephrology, Klinikum rechts der Isar
City
München
State/Province
Bavaria
ZIP/Postal Code
81675
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christoph Schmaderer, M.D.
Phone
0049-89-4140
Ext
6701
Email
christoph.schmaderer@lrz.tum.de
First Name & Middle Initial & Last Name & Degree
Georg Lorenz, M.D.
Phone
0049-89-4140
Ext
6704
Email
georg.lorenz@googlemail.com
First Name & Middle Initial & Last Name & Degree
Christoph Schmaderer, M.D.
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
28535525
Citation
Ronco C, La Manna G. Expanded Hemodialysis: A New Therapy for a New Class of Membranes. Contrib Nephrol. 2017;190:124-133. doi: 10.1159/000468959. Epub 2017 May 23.
Results Reference
background
PubMed Identifier
28085888
Citation
Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M, Hulko M, Boehler T, Glomb MA, Liehr K, Henning C, Templin M, Trojanowicz B, Ulrich C, Werner K, Fiedler R, Girndt M. Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial. PLoS One. 2017 Jan 13;12(1):e0169024. doi: 10.1371/journal.pone.0169024. eCollection 2017.
Results Reference
background
Learn more about this trial
Modulation of Inflammation by Medium Cut Off Membranes
We'll reach out to this number within 24 hrs